Jazz Pharmaceuticals said on Thursday its post-traumatic stress disorder (PTSD) drug failed in a mid-stage study, sending shares down more than 4% in after-market trading.
The trial failed to show a statistically significant reduction in PTSD symptoms, as measured on a scale, when compared with a placebo at 12 weeks.
https://finance.yahoo.com/news/1-jazz-pharmaceuticals-ptsd-drug-211718114.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.